- Home
- LSF vs CRVO Comparison
LSF vs CRVO Comparison
Compare LSF & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | CRVO |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 39.3M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LSF | CRVO |
|---|---|---|
| Price | $4.55 | $3.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $23.00 |
| AVG Volume (30 Days) | 78.2K | ★ 15.6M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $49,889,286.00 | $4,006,510.00 |
| Revenue This Year | $90.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.64 | ★ N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $1.96 | $2.13 |
| 52 Week High | $7.80 | $13.13 |
Technical Indicators
Market Signals| Indicator | LSF | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 52.02 |
| Support Level | $2.23 | $2.82 |
| Resistance Level | $5.11 | $4.19 |
| Average True Range (ATR) | 0.41 | 0.37 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 41.25 | 35.56 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.